IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
Real, Luis M. (Instituto de Biomedicina de Sevilla)
Neukam, Karin (Instituto de Biomedicina de Sevilla)
Herrero del Rio, Mª del Rocío (Universidad de Jaén)
Guardiola, Josep M. (Institut d'Investigació Biomèdica Sant Pau)
Reiberger, Thomas (Vienna HIV and Liver Study Group (Viena, Àustria))
Rivero-Juarez, Antonio (Instituto Maimónides de Investigación Biomédica de Córdoba)
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau)
Mandorfer, Mattias (Vienna HIV and Liver Study Group (Viena, Àustria))
Merino, Dolores (Hospital Juan Ramón Jiménez (Huelva, Andalusia))
Soriano, Vicente (Hospital Carlos III (Madrid))
Rivero, Antonio (Instituto Maimónides de Investigación Biomédica de Córdoba)
Macías, Juan (Instituto de Biomedicina de Sevilla)
Pineda, Juan A. (Instituto de Biomedicina de Sevilla)
Caruz, Antonio (Universidad de Jaén)
Universitat Autònoma de Barcelona

Data:	2014
Resum:	Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with rs12979860, has been discovered. Our objective was to assess the value of ss469415590 to predict SVR to pegIFN/RBV in Caucasian HCV-1/4-infected individuals and to compare its performance with that of rs12979860. Methods: 272 Caucasian HCV-1/4-infected patients who completed a course of pegIFN/RBV were genotyped for both rs12979860 and ss469415590 markers. Logistic regression models including factors with univariate association with SVR and each genetic marker were elaborated. The area under the receiver operating-characteristic curve (AUROC) was calculated for each model and both were compared. Results: Both markers were in LD (r = 0. 82). For rs12979860, 66 (64. 0%) CC versus 56 (33. 1%) T allele carriers achieved SVR (Adjusted OR = 4. 156, 95%CI = 2. 388-7. 232, p = 4. 647×10). For ss469415590, 66 (66. 0%) TT/TT versus 56 (32. 5%) -G allele carriers (Adjusted OR = 4. 783, 95% CI = 2. 714-8. 428, p = 6. 153×10) achieved SVR. The AUROC of the model including rs12979860 was 0. 742 (95%CI = 0. 672-0. 813) and of that based on ss469415590 was 0. 756 (95%CI = 0. 687-0. 826) (p = 0. 780). Conclusions: The ss469415590 variant shows an equivalent performance to predict SVR to pegIFN/RBV than the rs2979860 in Caucasian HCV-1/4-infected patients. © 2014 Real et al.
Ajuts:	Ministerio de Economía y Competitividad RD12/0017
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adult ; Alleles ; Antiviral Agents ; Coinfection ; European Continental Ancestry Group ; Female ; Follow-Up Studies ; Genotype ; Hepacivirus ; Hepatitis C, Chronic ; Humans ; Interleukins ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; ROC Curve ; Treatment Outcome
Publicat a:	PloS one, Vol. 9 Núm. 4 (18 2014) , p. e95515, ISSN 1932-6203

DOI: 10.1371/journal.pone.0095515
PMID: 24748394

6 p, 263.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats